A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IXORA-P
  • Sponsors Eli Lilly
  • Most Recent Events

    • 06 Feb 2018 Primary endpoint has been met. (Proportion of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75) in Q2W dose group versus the Q4W dose group) as per results published in British Journal of Dermatology.
    • 06 Feb 2018 Primary endpoint has been met. (Proportion of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1) in Q2 dose group versus the Q4W dose group) as per results published in British Journal of Dermatology.
    • 06 Feb 2018 Results published in the British Journal of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top